All In MedTech

Device Trial Radar · NCT04299282

CIED Implantation in Low BMI Patients

A Prospective, Randomized, Single-Center Study Evaluating CanGaroo in Low BMI Patients Undergoing Pacemaker, ICD, or S-ICD Implantation

Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 2021

Primary completion

Dec 2021

Study completion Mar 2022

Sponsor

Lead sponsor
Elutia Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 6, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to demonstrate a better degree of healing at the incision site and a decrease in erosion with CanGaroo compared to control patients (no envelope, CIED alone).

Conditions

  • Heart Diseases
  • Cardiac Disease

Interventions

  • CanGarooDevice

    CIED ECM envelope

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Healing at incision siteTime frame: 3 months post CIED implantation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.